Zinc sulfate (heptahydrate)
(Synonyms: 七水硫酸锌) 目录号 : GC39463
Zinc sulfate heptahydrate 是水合物，是七水合形式的硫酸锌。
Cas No.:7446-20-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Zinc sulfate heptahydrate is a hydrate that is the heptahydrate form of zinc sulfate.
[1]. Campos CG, et al. Targeted Metabolomics of Xylose-Fermenting Yeasts Based on Mass Spectrometry.Methods Mol Biol. 2019;1859:155-169.
| Cas No. | 7446-20-0 | SDF | |
| 别名 | 七水硫酸锌 | ||
| Canonical SMILES | O=S([O-])([O-])=O.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[Zn+2] | ||
| 分子式 | H14O11SZn | 分子量 | 287.55 |
| 溶解度 | DMSO: 100 mg/mL (347.77 mM); Water: 100 mg/mL (347.77 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4777 mL | 17.3883 mL | 34.7766 mL |
| 5 mM | 0.6955 mL | 3.4777 mL | 6.9553 mL |
| 10 mM | 0.3478 mL | 1.7388 mL | 3.4777 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Efficacy of Oral Zinc sulfate Supplementation on Clearance of Cervical Human Papillomavirus (HPV); A Randomized Controlled Clinical Trial
Asian Pac J Cancer Prev 2022 Apr 1;23(4):1285-1290.PMID:35485687DOI:10.31557/APJCP.2022.23.4.1285.
Aim: Human Papillomavirus is one of the most crucial infectious disease in gynecology disease. To assess the efficacy of supplemental zinc treatment in clearance of HPV infection. Methods: Eighty zinc-sufficient women between 21-55 years, with positive HPV DNA testing, and abnormal cervical cytology in Pap test (ASCUS or LISL) were randomly divided to case (n=40) and control group (n=40). Case group received oral tablets of Zinc sulfate twice a day for 3 months while control group received no placebo. During follow-up patients underwent repeat HPV DNA test and PAP test and were evaluated for clearance/persistence of HPV infection and regression/progression in the lesion grading. Results: As far as demographics, serum zinc levels and the relevant risk factors for persistence of HPV were concerned, there was no significant difference between two groups, except for the frequency distribution of HR-HPV which was significantly higher in case group. Zinc treatment for 3 months reduced the risk of persistence of HPV infection and progression from baseline cytology (OR = 0.130) (CI 95% 0.04-0.381; p <0.001) and 0.301 (95% CI 0.777-0.116; p = 0.012), respectively. Age, initial cytology, HPV type, and contraceptive method were not related to persistence of HPV. Serum zinc levels increased in the casr group as a result of oral zinc consumption for 3-month period, though without any statistical significance (p = 0.407). Conclusion: The results of the following study suggested that oral intake of Zinc sulfate supplement for 3 months increases the rates of HPV clearance and resolution of pre-existing cervical lesion.
Removal of chlorine from Zinc sulfate solution: a review
Environ Sci Pollut Res Int 2022 Sep;29(42):62839-62850.PMID:35831649DOI:10.1007/s11356-022-21896-2.
During zinc hydrometallurgy process, the chloride ions in the materials go into the leaching solution, which have abominable effects on equipment, electrowinning, and environment. So, it is necessary to remove chloride ions from Zinc sulfate solution. The present review outlines the current research of removal methods of chlorine by holistically highlighting the advantages and mechanisms. The main techniques used to remove chloride ions from Zinc sulfate solution are also discussed in detail. Among the methods, the precipitation method using copper slag to remove chlorine is widely used and the chlorine removal rate is up to 98%. In addition, the combination of electrochemistry and nanofiltration technology can form a closed-loop production process with less waste output and near-zero emissions. In addition, the challenges and possible future directions of chlorine removal from Zinc sulfate solutions are also delineated.
The influence of Zinc sulfate on neonatal jaundice: a systematic review and meta-analysis
J Matern Fetal Neonatal Med 2018 May;31(10):1311-1317.PMID:28372469DOI:10.1080/14767058.2017.1315659.
Introduction: Zinc sulfate may be a promising approach to treat neonatal jaundice. However, the results remain controversial. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of Zinc sulfate on hyperbilirubinemia among neonates. Methods: PubMed, EMbase, Web of science, EBSCO, Cochrane library databases, Ovid, BMJ database, and CINAHL were systematically searched. Randomized controlled trials (RCTs) assessing the effect of Zinc sulfate versus placebo on the prevention of jaundice in neonates were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcomes were total serum bilirubin (TSB) on three days and seven days, the incidence of hyperbilirubinemia. Meta-analysis was performed using random- or fixed-effect models. Results: Five RCTs involving 645 patients were included in the meta-analysis. Overall, compared with placebo, Zinc sulfate supplementation failed to significantly reduce TSB on three days (mean difference (MD) = 0.09 mg/dL; 95% confidence interval (CI) = -0.49 to 0.67; p = .77), TSB on seven days (MD = -0.37 mg/dL; 95% CI = -98 to 0.25; p = .25) as well as the incidence of hyperbilirubinemia (OR = 1.14; 95% CI = 0.74 to 1.76; p = .56). Zinc sulfate showed no influence on phototherapy requirement (OR = 0.90; 95% CI = 0.41 to 1.98; p = .79), but resulted in significantly decreased duration of phototherapy (MD = -16.69 h; 95% CI = -25.09 to -8.3 h; p < .0001). Conclusions: Zinc sulfate could not reduce the TSB on three days and seven days, the incidence of hyperbilirubinemia and phototherapy requirement, but lead to significantly decreased duration of phototherapy.
Comparison of Zinc sulfate and Zinc Threonine Based on Zn Bioavailability and Performance of Broiler Chicks
Biol Trace Elem Res 2021 Jun;199(6):2303-2311.PMID:32856251DOI:10.1007/s12011-020-02354-x.
The purpose of this study was to compare Zinc sulfate and zinc threonine chelate based on Zn bioavailability and performance of broiler chicks. The study was conducted in a completely randomized design with 256 day-old Ross 308 chicks and eight treatments including control treatment (no zinc supplementation), three levels of Zinc sulfate and zinc threonine chelate (40, 80, and 120 mg zinc per kg feed), and a common commercial chelate (Bioplex Zn®) supply 40 mg zinc per kg feed. The results of total period showed that threonine chelate group had the highest live weight compared with other treatments and lowest feed conversion ratio belonged to 80 and 120 ppm of zinc threonine chelate (p < 0.05). Zinc threonine chelate and commercial chelate treatments had the lowest cholesterol and LDL levels compared with other treatments (p < 0.05). Zinc chelate threonine which contains 80 and 120 ppm of zinc had the highest HDL and superoxide dismutase enzymes and the lowest heterophile to lymphocyte ratio compared with other treatments (p < 0.05). Relative bioavailability of zinc threonine to Zinc sulfate based on body weight, feed conversion ratio, cholesterol, LDL, HDL, superoxide dismutase enzyme, ash, and zinc content in tibia were 418.75, 173.91, 131.38, 159.43, 278.63, 193.45, 156.46, and 117.65%, respectively. According to the results of broiler performance and other traits measured in this study, it seems that the use of 80 ppm of zinc threonine chelate in the broiler diet is recommended in comparison with Zinc sulfate levels and other threonine chelate levels.
Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis
Ther Apher Dial 2012 Apr;16(2):142-5.PMID:22458392DOI:10.1111/j.1744-9987.2011.01032.x.
Pruritus is a common complaint in patients undergoing maintenance hemodialysis. The pathophysiology of pruritus in these patients is not well known, but the role of histamine release from mast cells has been reported. According to the inhibitory effects of zinc on histamine release and reported low levels of serum zinc in hemodialysis patients, we aimed to evaluate the effects of Zinc sulfate for the relief of pruritus in these patients. This double-blind, randomized, placebo-controlled trial was conducted on 40 adults with end stage renal disease (ESRD) who were on maintenance hemodialysis in two university hospitals in Isfahan, Iran. Patients were randomized to receive either Zinc sulfate (440 mg/day) or placebo for two consecutive months. Pruritus was assessed at baseline and then every two weeks using a numerical rating scale from 0 to 10 until one month after treatment. Drug side effects were also assessed along with pruritus. There were 40 patients with a mean age of 55.5 ± 15.2 (72.5% male) who completed the study. The two groups were similar in baseline characteristics. Pruritus was decreased in both groups after treatment but there was a significantly greater decrease in the Zinc sulfate group compared with placebo (P = 0.018). Patient compliance was good and no severe side effects were observed. Zinc sulfate (440 mg/day) is more effective than placebo for the relief of pruritus in patients under maintenance hemodialysis. Further studies with larger sample size, longer treatment duration and follow-up and with various dosages of Zinc sulfate are recommended.